Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership
Aleph Farms, reportedly the first company to grow cultivated steaks directly from non-modified cow cells, announced that it has acquired a manufacturing facility in Modi’in, Israel and certain related assets from biotechnology company VBL Therapeutics. In addition, Aleph Farms has signed a memorandum of understanding (MOU) with ESCO Aster, a vertically integrated contract manufacturing organization, to produce cultivated meat in Singapore. These agreements stand to increase Aleph Farms’ production capabilities and global impact as the company approaches commercialization.
“Israel and Singapore are the first two markets where we intend to launch our cultivated thin-cut steak. Building up production capacity quickly in those locations while keeping capital investment lean provides a clear roadmap to scalability,” says Didier Toubia, CEO and co-founder of Aleph Farms. “Beyond Israel and Singapore, we plan on building additional strategic assets worldwide as part of our effort to bring more security and resilience to food systems.”